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Summary.-Thirty-eight patients with metastatic melanoma were investigated
for lymphocyte function immediately prior to chemo-immunotherapy. The pre-
treatment immune tests were compared with normal control values and with re-
sponse to therapy. The "non-responder" group (but not "responder") had signifi-
cantly reduced values for lymphocyte, null-cell and E-rosette-cell counts compared
with controls. Lymphocytotoxicity (using a Chang target cell) showed the same
pattern, with depression of direct and K-cell cytotoxic capacity in non-responders
(statistically significant for direct cytotoxic capacity) but not in responders when
compared with controls. Eight patients were studied sequentially whilst on treat-
ment, and demonstrated considerable change (not statistically significant) in
lymphocytotoxicity, an untreated "control" patient showed little variation. "Recall"-
antigen skin testing showed no statistically significant difference between the patient
groups.
The data indicate that "non-T-cell activity" may be associated with response to
chemo-immunotherapy.
IMMUNOLOGICAL investigation of
malignant melanoma has been the subject
of considerable research. However, much
ofthis work has concentrated on attempts
to demonstrate "specific" immunity to
melanoma antigens. Humoral and cellular
cytotoxic assays have been employed in
the search; some authors describing
tumour "specificity" (Lewis et al., 1969;
Fossati et al., 1971) whilst others have
been unable to demonstrate such reactions
(Peter et al., 1975; Takasugi, Mickey and
Terasaki, 1973).
One explanation for the failure to
demonstrate a specific tumour-associated
response is that a high level ofnon-specific
cytotoxicity present in both healthy
controls and melanoma patients could
mask any "specific" cytotoxicity present
(Pavie-Fischer et al., 1975)
The study of non-specific lymphocyte
cytotoxicity per se in melanoma has been
infrequently documented and no reports
are available which describe the relation-
ship between pre-treatment immune re-
activity and response to chemo-immuno-
therapy.
The present investigation was under-
taken to determine whether patients with
metastatic melanoma (prior to chemo-
immunotherapy) were different from
healthy controls in terms of non-specific
cytotoxicity, and T and B lymphocyte
sub-populations and whether lymphocyte
function assays were different in patients
who subsequently responded to chemo-
immunotherapy, from those who were
unresponsive. In addition, some patients
were studied sequentially, to determine
whether an association exists between
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clin-ical tumour behaviour and lymphoid
function tested during the course of
treatment.
Various assays were employed, includ-
ing delayed hypersensitivity skin reaction
(to recall antigens) peripheral-blood
lymphocyte counts, formation of EAC
sheep rosettes (a B-lymphocyte marker,
(Bianco, Patrick and Nussenzweig, 1970))
E sheep rosettes, a T-lymphocyte marker,
(Lay et al., 1971; Jondal, Holm and
Wigzell, 1972) and a 51Cr-release assay of
lymphocyte effector function. In the
5ICr-release assay the following para-
meters were studied: direct spontaneous
cellular cytotoxicity, antibody-dependent
cellular cvtotoxicity (MacLennan and
Loewi, 1968; Perlmann and Holm, 1968),
and PHA-stimulated cellular cytotoxicity,
(Holm, Perlmann and Werner, 1964;
Holm, and Perlmann 1967) against Chang
target cells.
Antibody-dependent cellular cyto-
toxicitv is a function of "non-T cells"
(Harding et al., 1971), but the effector
cell ("K" cell) is different from B cells,
which are precursors of antibody-forming
cells (MacLennan, 1972). The PHA-stimu-
lated cytotoxicity appears to be mediated
by T cells (Perlmann and Holm, 1969;
O'Toole et al., 1974). The identity to the
human effector cell, responsible for spon-
taneous non-specific cytotoxicity is un-
clear. It has been reported to bear Fe
receptors (Jondal and Pross, 1.975; Hersev
et al., 1975) and is found in the non-T-cell
population (Peter et al., 1975; de Vries,
Cornian and Runks, 1.974).
MATERIALS AND METHODS
Patien1ts. Thirty-eight patients with
histologically proven malignant melanoma
were studied, (Table A and B). All patients,
except 2, had extranodal metastatic disease
involving more than one organ systenm.
Evaluation of disseminat,ion wNas by physical
examination, full blood count and differential,
liver and renal bio-chemical profiles, urinary
melanogens, chest X-rays, radiological skele-
tal survey, liver, brain and bone scans and
bone-marrow examiination wAlhen indicated
(Table 111).
No patient had received chemotherapy
prior to this study, and all surgery had been
performed at least 14 weeks previously.
Only 3 patients had received radiotherapy,
and this was to small fields (5 x 5 cm); the
shortest interval betwAeen irradiation and
immune testing was 4 weeks. Survival N-as
taken from the date of the first assessment of
immune status.
Immediately prior to the first course of
chemotherapy and before recall-antigen test-
ing, blood was taken for immunological
study. The chemo-immunotherapy regime
prescribed was as follows: 5(3-dimethyl-
triazeno)-imidazole-4 carboxamnide, (DTIC)
wAas administered i.v. at a dose of 250 mg/M2
for 5 consecutive days. On the first day the
patients also received a single i.v. injection
of vincristine (2 mg). The courses wiere
repeated (up to a total of 6) every 28 days.
BCG was given between courses of chemo-
therapy, 10 days from the start of the
preceding course. Dried BCG vaccine, per-
cutaneous (Glaxo) was -econstituted in 0-3 ml
sterile wAater and administered by a multiple-
puncture gun. Two applications of vaccine
(40 needle punctures, set at a 2 mm depth)
were given to each limb. BCG administration
was contrinued at monthly intervals followN-ing
completion of 6 courses of chemotherapy.
Response to therapy w-as taken as a 50% or
greater reduction in diameter ofa measurable
lesion, lasting at least 2 months and writhout
disease progression elsewhere.
In the sequential study, the patients' blood
samples were obtained at the start of each
course of chemotherapy and also, where
possible, on the day of BCG vaccination.
Tests of lymphocyte rosetting ability were
not undertaken in a sequential manner in
this particular study, due to logistic difficul-
ties. All the patients in this study completed
at least 3 courses of chemotherapy, and
sequential immune studies are available over
at least a 4-month period (Figs. 1 and 2).
The normal controls w\ere 14 individuals
employed in the hospital service and 7
relatives of patients (Table 1I). The median
age of controls wA-as 51 Vears (range 32-68)
and of the patients 49 years (range 22-75).
Tuberculin PPD (1:1000) 0.1 ml (Evans
Mledical Ltd, Speke, Liverpool, U.K.) SKSD
(10 u Streptokinase, 2-5 u Streptodornase)
0-1 ml (Lederle Labs, Pearl River, N.Y.,
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U.S.A.), and Candida albicans antigen 0.33%
(Bencard, Brentford, Middlesex, U.K.) were
used as the skin-test agents. The tests were
performed before treatment, using an intra-
dermal inoculation of0'1 ml into the forearm.
Results of the skin tests were read at 48 h
and the diameter of the induration and
erythema measured. A positive reaction was
defined as 5 mm or more of induration at
48 h.
Lymphocyte preparations.- Lymphocyte
suspensions for cytotoxic assays were pre-
pared from defibrinated peripheral blood
after incubation with finely divided iron and
sedimentation in 1% methylcellulose at 370C
using a magnet. The lymphocyte-rich super-
natant was washed x 3 in minimal essential
medium (MEM) and the concentration adjus-
ted to 3 x 105 cell/ml in MEM supplemented
with 10%/ heat-inactivated foetal calf serum,
2mM glutamine, 100 iu/ml streptomycin,
200 iu/ml penicillin and NaHCO3 buffer.
The lymphocytes comprised 96% or more of
the leucocytes present in the suspensions.
Lymphocyte preparations for the rosette tests
were obtained by Ficoll-Triosil gradient
centrifugation. After incubation with finely
divided iron, heparinised blood was diluted
with an equal volume of phosphate-buffered
saline (PBS) and layered on a mixture of
Triosil and 9%/ Ficoll. After centrifugation,
interface cells were collected and the cells
washed x 3 with PBS. The lymphocyte
puritywiththismethodofseparationwas93°%
or more of the leucocytes counted, the
remainder comprising 5% monocytes and 2%
neutrophils. Differential counts were per-
formed on smear preparations after Jenner-
Giemsa staining.
E rosettes.- Washed sheep red blood cells
(SRBC, Wellcome Reagents Ltd) were diluted
to a concentration of 2 x 108/ml in foetal
calf serum (FCS) and 0-2 ml of this suspen-
sion was mixed with 106 lymphocytes (in
0-2 ml FCS). The cells were sedimented by
gentle centrifugation and incubated for 18 h
at 40C. The cells werethen gentlyresuspended
and examined immediately in a haemo-
cytometer, the number of cells binding 3 or
more SRBC was determined as a percentage
of the total lymphocytes. All lymphocyte
preparations were tested in triplicate and the
means calculated.
EAC rosettes.-A suspension of washed
SRBC (containing 0-2 ml packed-cell volume)
was incubated for 30 min at 37°C with 4 ml
of rabbit anti-SRBC serum (1/500 final
dilution). The antibody-labelled SRBC were
then washed x 3 and incubated for a further
30 min at 370C, with human serum as a
complement source (1/20 final dilution). The
labelled SRBC were again washed x 3 and
the concentration adjusted to 2 x 108/ml in
PBS. Lymphocytes (106 in 0-2 ml PBS) were
incubated with 0-2 ml of labelled SRBC for
30 min at 37°C with shaking, and then
examined in a haemocytometer to determine
the percentage of rosette-forming cells.
Null-cell percentage was determined from
(100-sum (E + EAC rosette percentages)).
Cytotoxic assay.-Chang cells labelled with
51Cr sodium chromate (sp. act. 100-350
mCi/mmol, Amersham, Bucks.) were washed
and diluted to give a final concentration of
104 cell/ml in supplemented MEM. The
51Cr-release assay ofnon-specific cytotoxicity
against antibody-sensitised Chang target cells
(MacLennan and Loewi, 1968; Perlmann and
Holm, 1968) andthePHA-stimulatedlympho-
cytotoxicity against labelled Chang cells
(Holm et at., 1964; Holm and Perlmann,
1967) were performed as follows. The cultures
were set up in triplicate, containing 1 ml
of lymphocytes and 1 ml of Chang cells. The
test was divided into 3 sections. Chang
cells were tested with lymphocytes alone
(DCC) with lymphocytes and rabbit anti-
Chang serum diluted 1:105 (ADCC) and
lymphocytes withPHA (Purified Phytohaem-
agglutinin, Wellcome Reagents Ltd) 3 ,ug/ml
(PCC). Control tubes were set up with each
experiment, containing Chang cells alone,
with antibody or with PHA, but without
lymphocytes. These tubes gave the spon-
taneous 51Cr release. Maximal 51Cr release
was obtained by lysis with distilled water.
After standing at 37°C in a 5% C02 incubator
for 20 h, the tubes were centrifuged and
0 5 ml supernatant transferred to empty
tubes and counted on a gamma counter. The
ct/min was punched on to a paper tape which
was processed by a digital computer.
The 51Cr % release was computed for each
tube from
Supernatant ct/min x 4 - x I00 Total ct/mm (pellet + supernatant)
The maximal release was 88-99% and the
spontaneous release was 18-31%.
Results were expressed as the mean
corrected % 51Cr release (MCR) of the tripli-
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cates, and obtained from
Experimental 51Cr %0 release-
spontaneous 51Cr 00 release
Maximal 51Cr %0 release X 100
spontaneous 51Cr 00 release
The s.d. between triplicates was 30/%
TABLE IIT. 0/O Metastatic Involvement in
Responders and Non-responder Patient
Groups
Pulmonary/Hepat ic
Osseous/Cerebral
Nodal
Cutaneous
Responders -Non-responders
38 40
8 8
100 76
70 80
RESULTS
The two patient groups, responders and
non-responders, and the normal control
group were compared for differences in
lymphocyte count, DCC, ADCC, PCC,
E rosette %0, EAC rosette %0, "null" cell
%0 and the absolute E, EAC and null-cell
counts. Cytotoxic capacity (Go MCR x
lymphocyte count) was also calculated for
DCC, ADCC and PCC for individual
subjects and the median values compared.
Non-parametric statisticaltechniqueshave
been used because of non-normality of
data. As there were 3 groups, the Kruskal-
Wallis "one-factor analysis of variance
for ranks" was used initially and, if
statistically significaiit, each pair ofgroups
was then contrasted using the Mann-
Whitney U test at a reduced level of
statistical significance (100).
The distribution of metastases was
similar in the responder andnon-responder
patient groups (Table III). There was no
other obvious clinical difference between
these two groups before systemic therapy
commenced.
The lymphocyte count, cytotoxic capa-
city for DCC and ADCC, E rosette and
"null" cell counts were found to be
significantly different between the 3
groups using the Kruskal-Wallis test
(Table IV). The additional analysis dem-
onstrated that the difference was statisti-
cally significant between the non-responder
and control groups, with the following P
values: lymphocyte count 0'001, DCC
TABLE IV.-Median Values of In vitro Lyymphoid Testsfor Patients and Normals
(range in brack7ets)
Lymphocytes/p,l
DCC % MCR
ADCC % MCR
PCC % AICR
DCC Capacity
ADCC Capacity
PCC Capacity
E Rosette0/0
EAC Rosette %
Null %
E Rosette/pl
EAC Rosette/1l
Ntull cells/1l
Non-responders
1440
(392-4917)
11-0
(0-45 0)
37-7
(10-5-70-3)
44- 8
(2 - 1-79 - 5)
66
(1-712)
251
(92-1111)
313
(20-1115)
68-6
(40-5-91.0)
29- 1
(7 6--47-0)
4 -4
(0-26-4)
716
(262-1763)
320
(36-737)
72
(0-274)
* Statistically siginificant, (1' < 0 -05) Krtuskal-Wallis one-factor analysis of variance for ranks.
Responders
1536
(305-2530)
18-1
(0 67-2)
55-1
(5-3 -90-3)
57-1
(16-9-73-6)
179
(0-751)
566
(16-1090)
570
(50-1072)
66-3
(39-3-79-1)
23-9
(20-5-45-7)
10-2
(0-27-5)
1036
(176 2001)
401
(109--998)
128
(0-223)
Normals
1999
(1012-2689)
15-1
(2 0-27-5)
40-3
(18-4 55-0)
43 -6
(9 8-71-0)
220
(27-1387)
520
(159-903)
523
(176-792)
67-5
(53-0-79-3)
21 -9
(11 -8 33-5)
9-8
(0-25 5)
1294
(758- 2041)
441
(119-615)
186
(0-460)
J)
0 004*
0-13
0-11
0-27
0- 021*
0-021*
0-061
0-78
0-11
0-24
0- 002*
0-24
0.01*
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capacity 0-006, ADCC capacity 0 004,
E rosette count 0 0002, and "null" cell
count 0004.
Analysis of the other test values
revealed that the differences between the
groups were not statistically significant,
although examination of median values
showed a consistent pattern between the
3 groups (Table IV).
The median values of the responder
group: lymphocyte count 1536; DCC 18-1;
ADCC 55-1; PCC 5741 and their cytotoxic
capacity (179, 566, 570 respectively), were
all higher than in the non-responder
group, 1440, 11 0, 37 7, 44-8 and 66, 251,
313 respectively.
Higher values for null cell %, E-rosette
counts, EAC-rosette counts and null-cell
counts were also found in the responder
group (10.2, 1036, 401, 128 respectively)
than in the non-responder group (4.4,
716, 320, 72 respectively). The E, EAC
rosettes and null counts were highest in
normals, with respective values: 1294, 441,
186.
The values of E rosette % for the
non-responders (68.6), responders (66.3)
and normals (67.5) showed very little
difference. The EAC rosette %, however,
was higher in non-responders (29.1) than
in responders (23.9) and controls (21.9).
The skin reactivity to "recall" antigens
was similar in both patient groups. The
responder group showed 10/33 positive
NON-RESPONDERS
/Q MCR
PCC
0/0 MCR
ADCC
% MCR
DCC
80
60
40
20
80
60
40
20
0
80
60
40
Pre CT 1 2 3 4 S 6
Pre BCG 2 3 4 S
R.K
IVAVMs
2 3 4
2 3 4
J.G.
FiG. 1. Sequential reaction of lymphocyte toxicity (see text for details) of melanoma patients not
responding to 4 or more courses of chemo-immunotherapy (CT + BCG).
RESPONDERS
/o MCR 6
PCC 4
% MCRd
ADCC 4
%/o MCR 6
DCC 4
2
Pro rT
10
10
So
10
10
Rn
A.
rre t- i I X i q O1
Pre BCG 1 2 3 4 5 6
E.C.
< _~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
I S 3 4 5 6
1 2 3 4 5 6
).S.
I 2 3 4 5 6
2 34 5 6
M.A.
UNTREATED
.
.;
u 2 4 6 8 10
Months
D.M.
Fie. 2.-As for Fig. 1, for 3 melanoma patients responding to chemotherapy and one untreated.
A.Lp..A..
.... .. v ... ....... ...
...
AtAA A A a
20 , \1 .% iV\9 ...J - I V W- 12356-235-23 2 3 4 S 6 -2- 4 S 3 4 S 2 3 4
1 2 3 4 5 2 3 4 5 2 3 4
J.MK ML. C.M.
i
~~~~~~I I I1 A C A I -
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reactions (30.3%) compared with 21/63
(33-3%) in the non-responding group.
The sequential study of lymphocyte
cytotoxicity included 5 patients who were
non-responders (Fig. 1), 3 who were
responders and one untreated patient
with "stable" disease (Fig. 2). The
untreated patient. D.M. showed much less
variation in sequential tests than the
patients undergoing chemo-immuno-
therapy.
Comparison of sequential cytotoxicity
values for the individual patients showed
no significant changes. The patients'
results were also pooled for similar
occasions, but again no significant dif-
ference wasfoundbetween the cytotoxicity
values, using a Friedman 2-way non-
parametrical analysis.
DISCUSSION
This study demonstrates differences in
lymphoid-cell function between melanoma
patients and healthy controls. It also
suggests a difference in pre-treatment
lymphoid-cell function between patients
who subsequently respond and those who
fail to respond to systemic therapy. The
2 patient groups ("responder", "non-
responder") at the time of immunological
investigation were clinically similar, par-
ticularly with regard to the distribution of
metastases (Table III). It is, therefore,
unlikely that clinical response or the
immunological profile were dictated by a
particular pattern of metastatic desease.
However, this does not necessarily imply
that the pre-treatment tumour burden was
the same in both patient groups. It might
be expected that if the "responders" had a
smaller tumour mass than the "non-
responders", they would be more likely to
respond to therapy. Patient tumour mass
is as yet impossible to quantitate precisely,
but in the present investigation, there was
no obvious difference between the two
groups.
The lymphocyte count was significantly
less in the non-responder patient group
than in the healthy control group. The
median lymphocyte count for the respon-
der group was also lower than that of the
control group, but higher than that of the
non-responder group; the differences be-
tween patient groups were not however
significant. This relationship between res-
ponse and lymphocyte count has not
previously been clearly defined, although
lymphopenia has, in some series, been
related to poor survival (Riesco, 1970;
Papatestas and Kark, 1974).
The null-cell and E-rosette counts
demonstrated a similar significant dif-
ference between non-responder patients
and healthy controls, with the median
values of the responder group lying
midway between the other two. Therehave
been previous reports of T-cell depression
in cancer patients' blood (Wybran and
Fudenberg, 1973) but EAC resetting cells
in a variety of solid tumours, including
melanoma, have had normal values (An-
thony et al., 1975; Peter et al., 1975;
Whitehead et al., 1976). The presence of
null cells in the present study was asso-
ciated with lack of response. The increase
in null-cell number is partly a reflection of
the reduction in E- and EAC-rosette
numbers, and it is not possible to deter-
mine whether the lack of response was
associated with reduced E-rosette levels
alone or whether the change in null cells
was also important. A similar situation
was observed in patients with bronchial
carcinoma, although in this study it was
percentage of cells and not absolute
number that demonstrated significant
differences (Anthony et al., 1975). This is
in contrast to the present investigation,
where E rosette and EAC rosette percent-
ages showed very little differencebetween
patient groups and normal controls. It is
perhaps reasonable to analyse both per-
centages and absolute numbers until
more data have accumulated, to allow the
emphasis to be placed upon either one of
the values.
Delayed skin hypersensitivity to anti-
gens has been used as an in vivo measure
of cell-mediated immunity in melanoma
patients. In the present study, reactivity
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in both patient groups was depressed to
about the same extent and no significant
difference in skin reaction could be found
between responders and non-responders.
These data support other work describing
depressed skin reactivity in melanoma
(Catalona, Sample and Chretien, 1973)
but is at variance with reports of normal
skin reactivity (Ziegler et al., 1969) and of
the clinical significance attached to such
tests (Morton et al., 1-970). However, the
use of "skin test reactivity" shouild be
encouraged, despite the present and other
reports that lack statistically significant
differences, as it is the only in vivo method
routinely available for immunological
evaluation of patients.
Immune reactivity in vitro has been
related to tumour stage in some studies;
"tumour-specific "cellular immunity being
greater in localised than in generalised
disease (Cochran et al., 1973) and a
reduction in immunity being associated
with advancing disease (de AVries, Rumke
and Bernheim 1972; Heppner et al., 1973).
However, other authors, using PHA-
induced lymphocyte blastogenesis have
found either no difference between pa-
tients and controls (Ziegler et al., 1969;
Catalona et al., 1973) or a depression in
melanoma patients unrelated to the clini-
cal situation (Lui et al., 1975; Gatti,
G4arrioch and Good, 1970). Lymphocyte
microcytotoxicity assays have also failed
to relate to response rates (Vanwijck,
Bouillenne and Malek-Mansour, 1975;
Catalona et al., 1973; Berkelhammer et al.,
1975). Little attention has been directed at
"K"-cell activity as measured by ADCC,
but lowerreactivity in cancer patients than
in normal controls has been noted (Ting
and Terasaki, 1974; Peter et al., 1975).
However, the relationship with response
to therapy was not commented upon.
Inthepresent study, aconsistent pattern
of cytotoxicity was seen in the 3 groups.
The medians for the responder patients
showed no immunodepression relative to
controls. However, "non-T-cell" (DCC,
ADCC) cytotoxicitv was depressed in the
non-responders.
But, this depression was only statisti-
cally significant if "non-T-cell" function
was expressed in terms of the lymphocyte
count. The calculation is analagous to
that used in generating the rosetting-cell
counts. The implication is also similar-
that the "total" cytotoxicity of a func-
tionally defined subpopulation might be a
more biologically meaningful number to
use in statistical analysis.
The sequential study of cytotoxicity in
8 patients failed to demonstrate any
consistent pattern with repeated courses
of chemotherapy and BCG vaccination.
However, these patients, both responders
and non-responders, did exhibit more
fluctuation in cytotoxicity than the un-
treated patient with "stable" disease
(Figs. 1, 2) or normal controls assaved on
several occasions (Thatcher et al., 1977)
suggesting perturbation of cytotoxicity by
the chemo-immunotherapy and/or by alt-
eration in tumour load. A similar lack of
clinical correlation with a microcytoxicity
assay has been noted in melanoma
patients receiving immunotherapy alone
(Berkelhammer et al., 1975).
This investigation suggests that a high
level of "non-T-cell" cytotoxicity might
be important for a successful therapeutic
outcome in metastatic melanoma. The
median values of the DCC and ADCC
assays (albeit only significantly different
for "DCC capacity") were greater in res-
ponders, than innon-responders, andmight
be a reflection ofthe higher concentrations
of non-E-rosetting cells circulating in
these patients. Although T-cell numbers
and PCC were higher in responders than
in non-responders, the level of PCC was
near normal in the latter group and,
furthermore, these differences in PCC
were not statistically significant. A rela-
tionship between "non-T-cell" cytotoxicity
and clinical response might therefore be
postulated.
REFERENCES
kNTHoNY, H. Al., KIRK, J. A., MADSEN, K. E.,
MASON, J. K. & TEMPLEMAN, G. H. (1975) E an(i
EAC Rosetting Lymphocytes in Patieits with
Carcinoma of the Bronchuis. I. Some ParametersLYMPHOCYTE FUNCTION AND RESPONSE IN MELANOMA 761
of the Test and of its Prognostic Significance.
Olin. exp. Immunol., 20, 29.
BERKELHAMMER, J., MASTRANGELO, M. J., LAucIUs,
J. F., BODURTHA, A. J. & PREHN, R. T. (1975)
Sequential In vitro Reactivity of Lymphocytes
from Melanoma Patients Receiving Immuno-
therapy Compared with the Reactivity ofLymph-
ocytes from Healthy Donors. Int. J. Cancer, 16,
571.
BiANco, C., PATRICE, R. & NuSSENZVVEIG, V. (1970)
A Population of Lymphocytes Bearing Membrane
Receptor for Antigen-antibody Complement Com-
plexes. J. exp. Med., 132, 702.
CATALONA, W. J., SAMPLE, W. F. & CHRETIEN, P. P.
(1973) Lymphocyte Reactivity in Cancer Patients
Correlation with Tumour Histology and Clinical
Stage. Cancer, N. Y., 31. 65.
COCHRAN, A. J., MACKIE, R. N., THOMAS, C. E.,
GRANT, R. N., CAMERON-MOWAT, D. E. &
SPILG, W. G. S. (1973) Cellular Irmmunity to
Breast Carcinoma and Malignant Melanoma. Br.
J. Cancer 28, Suppl., 1, 153.
DE VRIES, J. E., RUMKE, P. & BERNHEIM, J. L.
(1972) Cytotoxic Lymphocytes in Melanoma
Patients. Int. J. Cancer, 9, 567.
DE VRIES, J. E., CORNIAN, S. & RUNKS, P. (1974)
Cytotoxicity of Non-T veraus T Lymphocytes
from Melanoma Patients and Healthy Donors on
Short and Long Term Cultured Melanoma Cells.
Int. J. Cancer, 14, 427.
FoSSATI, G., COLNAGHI, M. I., DELLA PORTA, G.,
CASCINELLI, N. & VERONESI, U. (1971) Cellular
and Humoral Immunity against Human Malig-
nant Melanoma. Int. J. Cancer, 8, 344.
GATTI, R. A., GARRIOCH, D. B. & GOOD, R. A. (1970)
Depressed PHA Responses in Patients with
Non-lymphoid Malignancies. Proceedings of the
Fifth Leukocyte Culture Conference. New York:
Academic Press, p. 339.
HARDING, B., PUDIFIN, D. J., GOTCH, F. M. &
MAcLENNAN, I. C. M. (1971) Cytotoxic Lympho-
cytes from Rats Depleted of Thymus Processed
Cells. Nature, New Biol., 232, 80.
HEPPNER, G. H., STOLBACH, L., BYRNE, M., CUM-
MINGS, F. J., McDONOUGH, E. & CALABRESI, P.
(1973) Cell Mediated and Serum Blocking Reac-
tivity to Tumour and Antigens in Patients with
Malignant Melanoma. Int. J. Cancer, 11, 245.
HERSEY, P., EDWARDS, A., EDWARDS, J., ADAMS, E.,
MILTON, G. W. & NELSON, D. S. (1975) Specificity
of Cell-mediated Cytotoxicity against Human
Melanoma Lines: Evidence for Non-specific
Killing by Activated T Cells. Int. J. Cancer, 16,
173.
HOLM, G., PERLMANN, P. & WERNER, B. (1964)
Phytohaemagglutinin-induced Cytotoxic Action
of Normal Lymphoid Cells and Cells in Tissue
Culture. Nature, Lond., 203, 841.
HOLM, G. & PERLMANN, P. (1967) Quantitative
Studies on Phytohaemagglutinin Induced Cyto-
toxicity by Human Lymphocytes against Homo-
logous Cells in Tissue Culture. Immunology, 12,
525.
JONDAL, M., HOLM, G. & WIGZELL, H. (1972)
Surface Markers on Human T and B Lymphocytes.
I. A Large Population of Lymphocytes Forming
Non-immune Rosettes with Sheep Red Blood
Cells. J. exp. Med., 136, 207.
JONDAL, M. & PROSS, H. (1975). Surface Markers
on Human B and T Lymphocytes. VI. Cyto-
toxicity against Cell Lines as a Functional
Marker for Lymphocyte Sub-populations. Int. J.
Cancer, 15, 596.
LAY, W. H., MENDES, N. F., BIANCO, C. & NuSSENz-
WEIG, V. (1971) Binding of Sheep Red Blood
Cells to a Large Population of Human Lympho-
cytes. Nature, Lond., 230, 531.
LEWIS, M. G., IKONOPISOV, R. L., NAIRN, R. C.,
PHILLIPS, T. M., HAMILTON-FAIRLEY, G., BODEN-
HAM, D. C. & ALEXANDER, P. (1969) Tumour
Specific Antibodies in Human Malignant Melan-
oma and their Relationship to Extent of Disease.
Br. med J., iii. 547.
LuI, V. K., KARPUCHAS, J., DENT, P. B., MCCUL-
LOCH, P. B. & BLAJCHMAN, M. A. (1975) Cellular
Immunocompetence in Melanoma Effect of
Extent of Disease and Immunotherapy. Br. J.
Cancer, 32, 323.
MACLENNAN, I. C. M. & LOEWI, G. (1968) The
Effect of Specific Antibody to Target Cells on
their Specific and Non-specific Interaction with
Lymphocytes. Nature, Lond., 219, 1069.
MAcLENNAN, I. C. M. (1972) Antibody in the In-
duction and Inhibition of Lymphocyte Cyto-
toxicity. Transplantn. Rev., 13, 67.
MORTON, D. L., EILBER, F. R., MALMGREN, R. A.
& WOOD, D. C. (1970) Inmmunological Factors
which Influence Response to Immunotherapy in
Malignant Melanoma. Surgery, 68, 158.
O'TOOLE, C., STEJSKAL, V., PERLMANN, P. &
KARLSSON, M. (1974) Lymphoid Cells Mediating
Tumour Specific Cytotoxicity to Carcinoma of the
Urinary Bladder; Separation of the Effector
Population Using a Surface Marker. J. exp. Med.,
139, 457.
PAPATESTAS, A. E. & KARK, A. E. (1974) Peripheral
Lymphocyte Counts in Breast Carcinoma. Cancer,
N.Y., 34, 2014.
PAVIE-FIsCHER, J., KOURILSKY, F. M., PICARD, F.,
BAUZET, P. & PUISSANT, A. (1975) Cytotoxicity of
Lymphocytes from Healthy Subjects and from
Melanoma Patients against Cultured Melanoma
Cells. Clin exp. Immunol., 21, 430.
PERLMANN, P. & HOLM, G. (1968) Studies on the
Mechanisms of Lymphocyte Cytotoxicity. In
Mechanism3 of Inflammation Induced by Immune
Reactivity. Eds P. A. Miescher & P' Graber.
Basle: Schaber & Co., p. 325.
PERLMANN, P. & HOLM, G. (1969) Cytotoxic Effects
of Lymphoid Cells In vitro. Adv. Immun., 11, 117.
PETER, H. H., PAVIE-FIsCHER, J., FRIDMAN, W. H.,
AUBERT, C., CESARINI, J. P., ROUBIN, R. &
KOURILSKY, F. M. (1975) Cell-mediated Cyto-
toxicity In vitro of Human Lymphocytes against
a Tissue Culture Melanoma Cell Line (IGR3).
J. Immun., 115, 539.
PETER, H. H., KALDEN, J. R., SEELAND, P., DIEHL,
V. & ECKERT, G. (1975) Humoral and Cellular
Immune Reactions "In vitro" against Allogeneic
and Autologous Human Melanoma Cells. Clin. exp.
Immun., 20, 193.
RIESCO, A. (1970) Five-year Cancer Cure: Relation
to Total Amount of Peripheral Lymphocytes and
Neutrophils. Cancer, 25, 135.
TAKASUGI, M., MICKEY, M. R. & TERASAKI, P. I.
(1973) Reactivity of Lymphocytes from Normal
Persons, on Cultured Tumour Cells. Cancer Re8.,
33, 2898.
THATCHER, N., GASIUNAS, N., POTTER, M. R.,
CROWTHER, D. & MOORE, M. (1977) Effects of762 N. THATCHER, M. K. PALMER, N. GASIUNAS AND D. CROWTHER
Intermittent 5 Fluorouracil and Adriamycin on
various Immune Parameters in Carcinoma
Patients with Reference to the Tumor load.
Cancer Immun. Immunother., (In press).
TINcG, A. & TERASAKI, P. I. (1974) Depressed
Lymphocyte Mediated Killing of Sensitised
Targets in Cancer Patients. Cancer Res., 34, 2694.
VANWIJCK, R., BOUILLENNE, C. & MALEK-MANSOTR,
S. (1975) Potentiation and Arming of Lymphocyte
Mediated Immunity by Sera from Melanoma
Patients. Eur. J. Cancer. 11, 267.
WHITEHEAD, R. H., THATCHER, J., TEASDALE, C.,
ROBERTS, G. P. & HuGHES, L. E. (1976) T. and B
Lymphocytes in Breast Cancer. Stage Relation-
ship and Abrogation of T Lymphocyte Depres-
sion by Enzyme Treatment In vitro. Lancet, i, 330.
WYBRAN, J. & FUDENBERG, H. H. (1973) Thymus
Derived Rosette Forming Cells in Various
Human Disease States: Cancer, Lymphoma,
Bacterial and Virus Infections and other Diseases.
J. clin. Invest., 52, 1026.
ZIEGLER, J. L., LEWIS, M. G., LUYOMBYA, J. M. S.
& KIRYABWIE, J. W. M. (1969) Immunologic
Studies in Patients with Malignant Melanoma in
Uganda. Br. J. Cancer, 23, 729.